Viewing Study NCT02397395

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:18 PM
Ignite Modification Date: 2026-01-29 @ 4:46 PM
Study NCT ID: NCT02397395
Status: WITHDRAWN
Last Update Posted: 2015-07-17
First Post: 2015-03-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
Sponsor: Janssen R&D Ireland
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Renal Impairment View
None End-stage Renal Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Renal Impairment View
None End-stage Renal Disease View
None Simeprevir View
None Daclatasvir View